Feasibility trial of adjuvant chemotherapy with paclitaxel and carboplatin after surgical resection in Japanese patients with non-small cell lung cancer: Report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0501

General Thoracic and Cardiovascular Surgery

Volumn 56, Issue 2, 2008, Pages 68-73

  Maruyama, Riichiroh ^a,b   Yoshino, Ichiro ^a,c   Tokunaga, Shoji ^a,d   Ohta, Morio ^a,e   Kato, Masato ^a,f   Yoshimine, Hiroyuki ^a,g   Yamazaki, Koji ^a,c   Nakanishi, Yoichi ^a,h   Ichinose, Yukito ^a,b  

^a STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e National Hospital Organization Okinawa National Hospital   (Japan)

^f HAMANOMACHI HOSPITAL   (Japan)

^g NAGASAKI UNIVERSITY   (Japan)

^h KYUSHU UNIVERSITY   (Japan)

Author keywords

Adjuvant chemotherapy; Carboplatin and Paclitaxel; Japanese patients; Multiinstitutional feasibility trial; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BRAIN INFARCTION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; HEALTH CARE ORGANIZATION; HUMAN; JAPANESE; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; THERAPY DELAY; TREATMENT DURATION; TREATMENT REFUSAL; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PNEUMONECTOMY; TREATMENT OUTCOME;

EID: 39749196090     PISSN: 18636705     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11748-007-0188-5     Document Type: Article

References (16)

1. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713-1721.
2. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteekiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
3. Strauss GM, Herndon J, Maddaus MA, Johnstone DW, Johnson EA, Watson DM, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 2004;22:621s (abstr 7019).
4. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Carpagnano F, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597.
5. Douillard JY, Rosell R, Delena M, Legroumellec A, Torres A, Carpagnano F, et al. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. J Clin Oncol 2005;23:624s (abstr 7013).
6. Scagliotti GV, Fossati R, Torri V, Crino L, Giaccone G, Silvano G, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003;95:1453-1461.
7. Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, Parmer MK, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004;26:173-182.
8. Schiller JH, Harrington DH, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
9. Kubota K, Nishiwaki Y, Ohashi Y, Saijo N, Ohe Y, Tamura T, et al. The four-arm cooperative study (FACS) for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;23:616.
10. Crowley J, Furuse K, Kawahara M, Fukushima M, Kawaguchi T, Williamson P, et al. Second Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): a model for testing populationrelated pharmacogenomics. J Clin Oncol 2006;24:376s (abstr 7050).
11. Sobin LH, Wittenkind C. TNM classification of malignant tumors. New York: Wiley-Liss; 1997.
12. Travis WD CT, Corrin B, Shimosato Y, Brambilla E, and collaborators from 14 Countries. World Health Organization. International histological classification of tumors. Histological typing of lung and pleural tumors. 3rd ed. Berlin: Springer Verlag; 1999.
13. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
15. Green S, Dahlberg S. Planned versus attained design in phase II clinical trials. Stat Med 1992;11:853-862.
16. Strauss GM, Herndon J, Maddaus MA, Johnstone DW, Johnson EA, Watson DM, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 2006;24:365s (abstr 7007).